SavedAdd your journal

Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2025 / Cilt: 50 Sayı: 3

Single Center Cetuximab Experience in Head and Neck Cancers

Baş-Boyun Kanserlerinde Tek Merkez Setüksimab Deneyimi

Seda Sali(Bursa Şehir Hastanesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Kliniği, Bursa, Türkiye.)0000-0001-8575-5477
Muhammed Abdurrahman Çelik(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa, Türkiye.)0009-0009-6430-8462
Alper Coşkun(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Bursa, Türkiye.)0000-0003-2444-6587
Eyüp Çoban(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Bursa, Türkiye.)0000-0002-1618-8082
Birol Ocak(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Bursa, Türkiye.)0000-0001-7537-1699
Ahmet Bilgehan Şahin(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Bursa, Türkiye.)0000-0002-7846-0870
Adem Deligönül(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Bursa, Türkiye.)0000-0002-3669-6391
Erdem Çubukçu(BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0002-0070-0889
Türkkan Evrensel(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Bursa, Türkiye.)0000-0002-9732-5340
Pages
463–469
Publication Date
2025-01-12
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median progression-free survival (PFS) of the patients was 4,6 months and the median overall survival (OS) was 7,1 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Head and neck squamous cell carcinomas (HNSCC) are cancers originating from epithelial cells of the oral cavity, pharynx and larynx.
📊
Key Findings & Data:Approximately 5% of patients are diagnosed in the metastatic stage.
💡
Conclusion & Impact:The median progression-free survival (PFS) of the patients was 4,6 months and the median overall survival (OS) was 7,1 months.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:cetuximab · cancer · neoplasm metastasis

Abstract

Head and neck squamous cell carcinomas (HNSCC) are cancers originating from epithelial cells of the oral cavity, pharynx and larynx. It is known to be the seventh most common cancer worldwide. Approximately 5% of patients are diagnosed in the metastatic stage. Within the first 2 years; approximately 50-60% of patients who complete primary treatment returning with relapse. In our study, we aimed to evaluate the efficacy of Cetuximab, an anti-epidermal growth factor (EGFR) monoclonal antibody which used for recurrent unresectable or metastatic HNSCC. The study included 38 patients. 33 (86,8%) of them were male and 5 (13,2%) were female. Median age was 55,5 years. Mean follow-up period was 14,95±18,17 months. The median progression-free survival (PFS) of the patients was 4,6 months and the median overall survival (OS) was 7,1 months. We found shorter survival compared to current literature. However, the rate of metastatic patients and the patients who had previously received chemotherapy were higher in our study.

Özet

Baş boyun squamöz hücreli kanserleri (BBSHK); oral kavite, farinks ve larinks yerleşimli epitelyal hücrelerden kaynaklanan kanserlerdir. Dünya genelinde yedinci en sık görülen kanser olduğu bilinmektedir. Hastaların yaklaşık %5’i metastatik evrede tanı almaktadır. Primer tedavisini tamamlayan hastaların ise yaklaşık %50-60’ı ilk 2 yıl içinde nüks etmektedir. Çalışmamızda nüks lokal tedavilere uygun olmayan ya da metastatik BBSHK hastalarının tedavisinde bir anti-epidermal büyüme faktörü (EGFR) monoklonal antikoru olan setüksimab tedavisinin etkinliğini değerlendirmeyi amaçladık. Çalışmaya 38 hasta dahil edildi. Bunların 33 (%86,8)’ ü erkek; 5 (%13,2)’i kadındı. Median yaş 55,5 idi. Ortalama takip süresi 14,95±18,17 aydı. Hastaların median progresyonsuz sağ kalım (PFS) süresi 4,6 ay ve median genel sağ kalım (OS) süresi ise 7,1 ay idi. Güncel literatür çalışmalarına kıyasla daha kısa sağ kalım süreleri saptadık. Ancak çalışmamızda metastatik hasta oranı ve daha önce kemoterapi almış olan hasta oranı yüksekti.

🔖

Cite This Article

Sali, S., Çelik, M. A., Coşkun, A., Çoban, E., Ocak, B., Şahin, A. B., Deligönül, A., Çubukçu, E., Evrensel, T., *, S. S. (2025). Single Center Cetuximab Experience in Head and Neck Cancers. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 50 Sayı: 3, 463–469. https://doi.org/10.32708/uutfd.1510864

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Johnson DE, Burtness B, Leemans CR, et al: Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92, 2020
  2. Ferlay J, Ervik M, Lam F, et al (eds): Cancer Today (powered by GLOBOCAN 2018). Lyon, France, 2018
  3. Sacco, A., Cohen, E., 2015. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 33 (29), 3305–3313.
  4. Brockstein, B., Vokes, E., 2020. Treatment of Metastatic and Recurrent Head and Neck Cancer. In: UpToDate [database on the internet]. [cited Feburary 2020]. Available from:. UpToDate, Altham (MA). https://www.uptodate.com/contents/treatment-ofmetastatic-and-recurrent-head-and-neck-cancer#H1.
  5. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
  6. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibodydependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80.
  7. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-42.
  8. Rivera, F., García-Castaño, A., Vega, N., Vega-Villegas, M. E., & Gutiérrez-Sanz, L. (2009). Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert review of anticancer therapy, 9(10), 1421-1428.
  9. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928.
  10. Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E.,. & Benhamou, E. (2017). Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. The Lancet Oncology, 18(8), 1022-1039.
  11. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101:2222.
  12. Fortin, A., Wang, C. S., & Vigneault, É. (2009). Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. International Journal of Radiation Oncology* Biology* Physics, 74(4), 1062-1069.
  13. Eichler, M., Keszte, J., Meyer, A., Danker, H., Guntinas–Lichius, O., Oeken, J.,. & Singer, S. (2016). Tobacco and alcohol consumption after total laryngectomy and survival: A German multicenter prospective cohort study. Head & neck, 38(9), 1324-1329.